ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/GPRC5D
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/GPRC5D
7
trial(s) found.
NCT06630806
Haem
Phase 1
Recruiting
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
TED18162
)
anti-GPRC5D monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06297226
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (
QUINTESSENTIAL
)
autologous CAR-T cell therapy,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06106945
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma (
D7230C00001
)
anti-GPRC5D antibody-drug conjugate
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06083207
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (
CIBI3003A101
)
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Private Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000438459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (
ZEPFHR-MM-Domain-1
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Recruitment Country and State
NSW (7)
VIC (7)
QLD (4)
WA (4)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (2)
Trial Type
Haem (7)
Cancer Therapy Class
GPRC5D
100%
cereblon
43%
BCMA
43%
CD38
29%
proteasome
14%
Facility
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2500 - Wollongong - Wollongong Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
3168 - Clayton - Monash Medical Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy